Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus activity in a Phase 2 study
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
Johnson & Johnson Receives FDA Approval for TRUFILL n?BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Johnson & Johnson's INLEXZO delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New long-term data reinforces TREMFYA® as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
SAGA Metals Highlights Radar Titanium Opportunity as North America Confronts Defense Driven Titanium Supply Chain Risks
RETRANSMISSION: Blackrock Silver Closes C$15 Million Private Placement Led By a C$7 Million Investment from Eric Sprott
